Gut barrier disruption by an enteric bacterial pathogen accelerates insulitis in NOD mice
- 1.9k Downloads
Increased exposure to enteric microbes as a result of intestinal barrier disruption is thought to contribute to the development of several intestinal inflammatory diseases; however, it less clear whether such exposure modulates the development of extra-intestinal inflammatory and autoimmune diseases. The goal of this study was to examine the potential role of pathogenic enteric microbes and intestinal barrier dysfunction in the pathogenesis of type 1 diabetes.
Using NOD mice, we assessed: (1) intrinsic barrier function in mice at different ages by measuring serum levels of FITC-labelled dextran; and (2) the impact on insulitis development of infection by strains of an enteric bacterial pathogen (Citrobacter rodentium) either capable (wild-type) or incapable (lacking Escherichia coli secreted protein F virulence factor owing to deletion of the gene [ΔespF]) of causing intestinal epithelial barrier disruption.
Here we demonstrate that prediabetic (12-week-old) NOD mice display increased intestinal permeability compared with non-obese diabetes-resistant and C57BL/6 mice. We also found that young (4-week-old) NOD mice infected with wild-type C. rodentium exhibited accelerated development of insulitis in concert with infection-induced barrier disruption. In contrast, insulitis development was not altered in NOD mice infected with the non-barrier-disrupting ΔespF strain. Moreover, C. rodentium-infected NOD mice demonstrated increased activation and proliferation of pancreatic-draining lymph node T cells, including diabetogenic CD8+ T cells, compared with uninfected NOD mice.
This is the first demonstration that a loss of intestinal barrier integrity caused by an enteric bacterial pathogen results in the activation of diabetogenic CD8+ T cells and modulates insulitis.
KeywordsCitrobacter rodentium ΔespF Citrobacter rodentium Enteric bacterial infection Gut barrier disruption Insulitis Intestinal barrier NOD mice Type 1 diabetes
Strain lacking Escherichia coli secreted protein F virulence factor
Carboxyfluorescein succinimidyl ester
Cytotoxic T lymphocyte
Escherichia coli secreted protein F virulence factor
Islet-specific glucose-6-phosphatase catalytic subunit-related protein
Normally, the intestinal epithelium provides a protective barrier preventing both pathogenic and commensal bacteria from escaping from the intestinal lumen and activating the systemic immune system. Disruption of this delicate barrier promotes the initiation and development of intestinal autoimmune diseases such as coeliac disease  and inflammatory bowel disease . Impaired intestinal barrier function has also been detected in rodent models of type 1 diabetes [3, 4, 5, 6, 7] and in type 1 diabetes patients and their relatives [8, 9, 10, 11, 12]. Changes in the intestine, induced by dietary or enteric antigens, have been proposed as causative factors in the course of type 1 diabetes [13, 14]; however, the role of the gut and enteric microbes in type 1 diabetes remains unclear. We thus propose that impaired intestinal barrier function in diabetes-prone individuals may allow commensal or pathogenic enteric bacterial antigens to elicit inflammatory signals that promote type 1 diabetes.
Type 1 diabetes is the result of an immune-mediated destruction of insulin-producing beta cells in the pancreas, predominantly by cytotoxic T lymphocytes (CTLs) . The primary activation of diabetogenic CTLs occurs within the pancreatic and gut-associated lymph nodes (LNs) [16, 17]. Lymphocytes within the pancreatic LNs thus communicate with the intestinal immune system, and the gut and its luminal contents may contribute to the initiation of type 1 diabetes . Luminal antigens from the gut are preferentially transported to the pancreatic LNs, resulting in the local proliferation of antigen-specific CTLs . Additionally, diabetogenic CTLs express the gut-homing receptor α4β7 integrin [19, 20, 21] and CTLs activated in the gastrointestinal (GI) tract of NOD mice home to islets that express the mucosal-homing receptor mucosal addressin cell adhesion molecule-1 [19, 20, 21].
Based on these findings, we hypothesised that an impaired intestinal barrier function exposing the immune system to GI microbes and other luminal antigens might provide an inflammatory stimulus that drives the autoimmune response in type 1 diabetes. In this study, we demonstrate that prediabetic NOD mice develop an intrinsic intestinal barrier dysfunction by 12 weeks of age. Moreover, colonic infection of young (4-week-old) NOD mice by a bacterial pathogen (wild-type [WT] Citrobacter rodentium) that specifically damages the intestinal epithelial barrier promotes the development of insulitis, which was not observed when these mice were infected with a mutant strain of C. rodentium (lacking Escherichia coli secreted protein F virulence factor [ΔespF]) that is unable to disrupt the intestinal epithelial barrier . We show that enteric infections can modify islet inflammation in type 1 diabetes and demonstrate that enteric infection-induced damage of intestinal barrier function may affect the early stages of development of type 1 diabetes.
Mice, bacteria and infection
8.3 NOD mice, expressing the rearranged T cell receptor genes of the diabetogenic CTL clone NY8.3, have been previously described  and were provided by P. Santamaria (University of Calgary, Calgary, AB, Canada). 8.3 NOD mice and NOD mice (Jackson Laboratory, Bar Harbor, ME, USA) were housed and bred under SPF conditions at the Child and Family Research Institute (Vancouver, BC, Canada), and used between 4 and 12 weeks of age. Mice were fed with LabDiet 5053 Irradiated Picolab Rodent Diet 20 (PMI Nutrition International, Jamieson’s Pet Foods International, Vancouver, BC, Canada). Infection of mice and culturing of WT and ΔespF C. rodentium was performed as previously described [22, 24]. In brief, mice were infected by oral gavage with 0.1 ml of an overnight bacterial culture in Luria broth containing approximately 2.5 × 108 colony-forming units (CFUs) of WT or ΔespF C. rodentium. To enumerate C. rodentium, whole gut tissues (including stools) or LNs were collected from infected mice, homogenised, plated on MacConkey plates, incubated at 37°C, and colonies counted the following day [22, 24]. Experiments were conducted as approved by the institutional animal ethics committee.
The FITC-dextran assay was performed as described . Briefly, for assessment of barrier function in the upper GI tract, 0.15 ml of 80 g/l of FITC-dextran (FD4; Sigma-Aldrich, Oakville, ON, Canada) in PBS was introduced to mice by oral gavage, whereas 0.1 ml was introduced by enema for studies assessing colonic barrier function following C. rodentium infection. After 2 h (enema) or 4 h (oral gavage), serum was collected by cardiac puncture and measured with a fluorimeter (Victor X3; PerkinElmer, Waltham, MA, USA).
Insulitis scoring and diabetes assessment
Paraffin-embedded sections of the pancreas were stained with haematoxylin and eosin, and examined by light microscopy (BX61TRF; Olympus, Tokyo, Japan). Insulitis severity was assessed as described  in normoglycaemic mice by an observer blinded to tissue source by counting at least 30 pancreatic islets per mouse from four parallel sections of different cut levels of the pancreas. Mice that became diabetic within 12 weeks of age were censored in each group (3/30 uninfected; 2/25 WT C. rodentium-infected; and 4/24 ΔespF C. rodentium-infected NOD mice) because of a paucity of islets available for counting. Blood glucose was measured using Elite glucostrips and glucometer (Bayer, Etobicoke, ON, Canada). Animals were considered to be diabetic when two consecutive measurements exceeded 14 mmol/l. The degree of insulitis was classified into four categories: 0, no insulitis; 1, peri-insulitis with or without minimal lymphocytic infiltration in islets; 2, invasive insulitis with <50% of lymphocytic infiltration of islets; or 3, invasive insulitis with ≥50% of lymphocytic infiltration of islets.
Adoptive transfer, LN preparation and flow cytometry analysis
Naive 8.3 NOD CD8+ T cells (islet-specific glucose-6-phosphatase catalytic subunit-related protein [IGRP]-specific [islet antigen] CD8+ T cells) were prepared and purified from the peripheral LNs and spleens of transgenic mice and labelled with CFSE (carboxyfluorescein succinimidyl ester 5 μmol/l; Molecular Probes-Invitrogen, Burlington, ON, Canada) . The labelled cells (1 × 107) were transferred to WT C. rodentium-infected NOD recipients i.v. via a tail vein at 10 days after infection. LN single-cell suspensions were prepared, stained and examined on a FACSCalibur flow cytometer (BD Bioscience, San Jose, CA, USA) as described .
Two-tailed Student’s t test and non-parametric Mann–Whitney t tests were used to calculate statistical significance where indicated. All statistical analysis was conducted using Prism 3 GraphPad software (La Jolla, CA, USA).
Intrinsic intestinal barrier dysfunction in prediabetic NOD mice
Recent evidence suggests a link between intestinal barrier dysfunction, subsequent enteropathies and an increased risk of type 1 diabetes in both rodent models and humans [1, 2, 4, 5, 6, 11, 12, 14]. To explore the role of intestinal barrier permeability in the pathogenesis of type 1 diabetes, we examined intestinal epithelial barrier function in the NOD mouse.
WT C. rodentium infection disrupts intestinal barrier function in NOD mice
C. rodentium translocates to the mesenteric and pancreatic LNs of infected NOD mice
We next assessed WT C. rodentium CFUs within the colon and caecum, and determined if the resulting barrier disruption led to this pathogen reaching the mesenteric and pancreatic LNs. WT C. rodentium counts were higher in these LNs, and in the caecum and colon of infected NOD mice compared with infected C57BL/6 mice (Fig. 2b). There were no differences in WT C. rodentium numbers detected in the pancreas, spleen or liver in either mouse strain (data not shown). The WT C. rodentium recovered from the LNs of infected mice may reflect those microbes specifically transported to these lymphoid tissues by dendritic cells or macrophages, either as a result of sampling the intestinal lumen or following phagocytosis of C. rodentium that passively leaked across a disrupted intestinal barrier.
WT but not ΔespF C. rodentium accelerates insulitis in NOD mice
To determine if the accelerated insulitis was because of C. rodentium’s ability to disrupt the intestinal epithelial barrier integrity, we also infected NOD mice with a mutant strain of C. rodentium that lacks espF (ΔespF). This bacterial protein plays a primary role in C. rodentium’s ability to disrupt intestinal epithelial barrier function . Infection of NOD mice with ΔespF C. rodentium did not increase intestinal barrier permeability as measured by serum FITC-dextran levels (Fig. 2a), nor did it increase insulitis scores (Fig. 3), compared with uninfected mice. These results indicate that intestinal barrier disruption is a prerequisite for C. rodentium infection to influence the development of insulitis.
WT C. rodentium increases the proliferation and activation of CD8+ and CD4+ T cells in NOD mice
The present study demonstrates that alterations in GI barrier function modify insulitis, a precursor stage of the extra-intestinal autoimmune disease, type 1 diabetes. NOD mice develop an overt and spontaneous intestinal barrier defect at the time of insulitis that precedes the development of type 1 diabetes. Variability in the levels of spontaneous barrier disruption suggests a heterogeneous defect. Importantly, infection of NOD mice with the enteric bacterial pathogen, C. rodentium, accelerates the development of insulitis, but only when this pathogen is capable of disrupting colonic epithelial barrier function. The increased lymphocytic infiltration within the islets of WT C. rodentium-infected NOD mice occurs concurrently with the increased activation of both polyclonal and diabetogenic CTLs. These data suggest that exposure to enteric pathogens (i.e. bacteria as demonstrated here, or viral pathogens) and possibly other dietary or gut antigens may increase the risk of activating diabetogenic CTLs and subsequently developing insulitis and type 1 diabetes.
There is mounting evidence suggesting that intrinsic or induced intestinal barrier defects skew the intestinal immune environment or the commensal microbiota to promote type 1 diabetes . For example, type 1 diabetes has been epidemiologically linked to coeliac disease, where gut barrier dysfunction has also been proposed as a predisposing factor [2, 13]. Wheat gluten has been identified as a main contributor of gut barrier dysfunction in coeliac disease and as a potential source of gut barrier dysfunction in type 1 diabetes [2, 13]. NOD mice fed a wheat gluten diet develop a Th1 cytokine bias in the gut . This diet promotes small intestinal enteropathy , and increases the incidence of diabetes . However, a recent report has shown conflicting evidence of the role of wheat gluten in type 1 diabetes in NOD mice: NOD mice fed either gluten-enriched or gluten-free diets showed a delay in the development of type 1 diabetes . Dietary antigens inclusive of wheat gluten may thus have an important role in modulating diabetes onset. Additionally, viral infections are associated with the onset of type 1 diabetes (particularly enteroviruses and rotaviruses) and also affect gut permeability [33, 34]. Reports have shown that children with type 1 diabetes have increased barrier defects in their small intestines ( and reviewed in ) and have a higher incidence of enteroviral infections . Moreover, recent studies have also implicated innate recognition of enteric commensal microbes in the modulation of diabetes suffered by NOD mice . An altered commensal gut flora because of interrupted toll-like receptor (TLR) signalling was shown to prevent diabetes. In contrast, relatively little is known about the potential role of enteric bacterial pathogens in modulating the occurrence of type 1 diabetes.
We show that prediabetic NOD mice develop an intrinsic ‘leaky’ gut. This finding has been well characterised in the BioBreeding rat model of type 1 diabetes [3, 5, 6]. Watts et al.  have suggested that intrinsic gut leakiness in BioBreeding rats may be caused by an increase in endogenous zonulin, a protein involved in modulating intestinal tight junctions. This increased zonulin has been shown to be present in type 1 diabetes patients and their relatives . In contrast, the mechanism that leads to intrinsic gut leakiness in the NOD mouse remains unclear. Hadjiyanni et al.  described a barrier defect in the jejunum (small intestine) of 7- to 10-week-old NOD mice, but did not determine whether this defect contributes to, or alternatively is the result of islet inflammation. We demonstrated increased permeability to oral FITC-dextran (probably caused by small bowel barrier change) at 12 weeks of age (prior to the onset of diabetes), but not at 4–8 weeks. In contrast to Hadjiyanni et al., we demonstrate that infection with WT C. rodentium several weeks prior to the development of insulitis induces significant barrier disruption in the large intestine (using the FITC-dextran enema technique [Fig. 2a]) and accelerates insulitis (Fig. 3) in NOD mice. This acceleration was not observed when NOD mice were infected with the mutant C. rodentium strain (ΔespF) (Fig. 3) that does not damage intestinal barrier integrity . Thus, barrier dysfunction at different sites within the GI tract (small bowel or large bowel), and at different times, may modulate the development of type 1 diabetes.
While C. rodentium infection of young NOD mice promotes insulitis, i.v. infection with attenuated Salmonella enteriditis serotype typhimurium (Salmonella typhimurium) halted type 1 diabetes onset in NOD mice . These differences in the impact on type 1 diabetes development may reflect that intestinal barrier disruption (as seen with C. rodentium infection) does not occur when Salmonella typhimurium is administered parenterally and suggests that disruption of the gut barrier contributes to pathogen-accelerated insulitis. This hypothesis is supported by the observation that chemical disruption of the intestine with 2% (wt/vol.) dextran sodium sulphate in the drinking water also leads to the proliferation of diabetogenic T cells and accelerates development of insulitis .
Innate and adaptive immune responses coordinated by epithelial TLR signalling modulate the enteric flora and in turn are affected by gut microbes [37, 39, 40, 41]. Epithelial TLR signalling is critical in maintaining intestinal epithelial integrity . Disruption of this homeostasis as a result of a dysregulated interaction between TLRs and enteric bacteria promotes both inflammatory bowel disease and type 1 diabetes [14, 42]. It is possible that enhanced antigen presenting cell-mediated TLR signalling is induced by enteric organisms breaching a gut barrier and that this promotes insulitis. Whether disease onset is modulated via epithelial and/or antigen presenting cell-mediated TLR or other innate signalling induced by enteric organisms (either commensals or pathogens) remains to be clarified.
Although there are no definitive clinical studies linking enteric bacterial infections to the development of human type 1 diabetes, there are a growing number of reports of type 1 diabetes patients who concomitantly present with intestinal enteropathies [8, 9, 10, 11, 12, 35]. Our results demonstrate that intestinal barrier dysfunction, in this case mediated by the enteric bacterial pathogen, C. rodentium, is a catalyst for the accelerated development of insulitis and for the priming of CD8+ T cells that are potentially diabetogenic. As enteric infections may also modulate regulatory T cell subsets, future studies are needed to address the ultimate impact of C. rodentium upon type 1 diabetes. Further studies are also warranted to determine if other enteric infections (i.e. enteroviruses) and drugs (i.e. non-steroidal anti-inflammatory drugs) that damage the intestinal barrier accelerate the development of spontaneous diabetes in diabetes-prone animal models. Conversely, manipulation of intestinal barrier integrity may offer therapeutic avenues for the treatment of type 1 diabetes.
This work was supported by a grant from the Juvenile Diabetes Research Foundation to J. P. Dutz, B. A. Vallance and D. L. Gibson. A. S. Lee is supported by a Michael Smith Foundation of Health Research (MSFHR) Junior Graduate Studentship. D. L. Gibson is supported by a Canadian Association of Gastroenterology/AstraZeneca/CIHR Post-Doctoral Research Initiative award and an MSFHR Post-Doctoral Fellow award. B. A. Vallance is the Children with Intestinal and Liver Disorders (CHILD) Foundation Research Scholar, an MSHFR Scholar and the Canada Research Chair in Paediatric Gastroenterology. J. P. Dutz is an MSFHR Senior Scholar, Child and Family Research Institute (CFRI) Senior Scholar and Senior Scientist at the CFRI. We are grateful to the Dutz and Vallance laboratories for their comments and support.
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.